# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company" or "Virios Therapeutics"), a development-stage biotechno...
Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of...
- New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally –- Active Long-COVID c...